Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …

Background There are few effective treatment options for patients with recurrent or metastatic
head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and …

Background Xerostomia is the most common late side-effect of radiotherapy to the head and
neck. Compared with conventional radiotherapy, intensity-modulated radiotherapy (IMRT) …

Radiotherapy plays a central part in curing cancer. For decades, most research on improving
treatment outcomes has focused on modulating radiation-induced biological effects on …

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune
response associated with immunological memory, provided they display sufficient …

The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think
about cancer treatment. Even so, for most types of cancer, only a minority of patients currently …

The biodistribution and pharmacokinetics of 111 In-DTPA-labeled pegylated liposomes (IDLPL)
were studied in 17 patients with locally advanced cancers. The patients received 65–…

Objectives We report 2-year results from CheckMate 141 to establish the long-term efficacy
and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with …

Purpose: To conduct a phase I clinical trial with a second-generation oncolytic herpes simplex
virus (HSV) expressing granulocyte macrophage colony-stimulating factor (Onco VEX GM-…

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …